share_log

东吴证券4月19日发布研报称，给予爱博医疗（688050.SH）买入评级。评级理由主要包括：1）毛利率由于收入结构变化略有下降；2）隐形眼镜业务第二增长曲线打开；3）持续加强研发投入，新品临床进展良好。（每日经济新闻）

Dongwu Securities released a research report on April 19 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) gross margin declined slightly due to changes in revenue structure; 2) the second grow

Zhitong Finance ·  Apr 19 10:25
Dongwu Securities released a research report on April 19 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) gross margin declined slightly due to changes in revenue structure; 2) the second growth curve for the contact lens business opened; 3) Continued increase in R&D investment, and the clinical progress of new products is good. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment